Bio-View Ltd (BIOV) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Bio-View Ltd (BIOV) has a cash flow conversion efficiency ratio of 0.049x as of December 2022. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (ILA1.38 Million ≈ $3.70K USD) by net assets (ILA28.28 Million ≈ $75.81K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Bio-View Ltd - Cash Flow Conversion Efficiency Trend (2009–2024)
This chart illustrates how Bio-View Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Bio-View Ltd balance sheet liabilities for a breakdown of total debt and financial obligations.
Bio-View Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Bio-View Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Whitebark Energy Ltd
AU:WBE
|
0.308x |
|
Eversafe Rubber Bhd
KLSE:0190
|
0.168x |
|
ArcWest Exploration Inc
V:AWX
|
-0.006x |
|
AquaBounty Technologies Inc
NASDAQ:AQB
|
0.480x |
|
Smart Equity AG
HM:SE3
|
N/A |
|
Opyl Ltd
AU:OPL
|
1.994x |
|
JIADE LIMITED Common stock
NASDAQ:JDZG
|
0.040x |
|
Compodium International AB
ST:COMPDM
|
0.043x |
Annual Cash Flow Conversion Efficiency for Bio-View Ltd (2009–2024)
The table below shows the annual cash flow conversion efficiency of Bio-View Ltd from 2009 to 2024. For the full company profile with market capitalisation and key ratios, see Bio-View Ltd market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ILA22.95 Million ≈ $61.52K |
ILA-3.11 Million ≈ $-8.33K |
-0.135x | -2515.71% |
| 2023-12-31 | ILA27.30 Million ≈ $73.20K |
ILA153.00K ≈ $410.19 |
0.006x | -83.63% |
| 2022-12-31 | ILA28.28 Million ≈ $75.81K |
ILA968.00K ≈ $2.60K |
0.034x | -71.36% |
| 2021-12-31 | ILA27.16 Million ≈ $72.82K |
ILA3.25 Million ≈ $8.71K |
0.120x | +273.69% |
| 2020-12-31 | ILA25.07 Million ≈ $67.21K |
ILA802.00K ≈ $2.15K |
0.032x | -68.02% |
| 2019-12-31 | ILA24.95 Million ≈ $66.89K |
ILA2.50 Million ≈ $6.69K |
0.100x | +271.76% |
| 2018-12-31 | ILA22.75 Million ≈ $60.99K |
ILA-1.32 Million ≈ $-3.55K |
-0.058x | -2629.85% |
| 2017-12-31 | ILA23.45 Million ≈ $62.88K |
ILA54.00K ≈ $144.77 |
0.002x | -98.29% |
| 2016-12-31 | ILA27.61 Million ≈ $74.01K |
ILA3.73 Million ≈ $9.99K |
0.135x | -33.43% |
| 2015-12-31 | ILA22.99 Million ≈ $61.63K |
ILA4.66 Million ≈ $12.50K |
0.203x | +12.52% |
| 2014-12-31 | ILA18.18 Million ≈ $48.75K |
ILA3.28 Million ≈ $8.79K |
0.180x | +196.72% |
| 2013-12-31 | ILA15.65 Million ≈ $41.95K |
ILA-2.92 Million ≈ $-7.82K |
-0.186x | -232.37% |
| 2012-12-31 | ILA16.69 Million ≈ $44.76K |
ILA2.35 Million ≈ $6.30K |
0.141x | -34.69% |
| 2011-12-31 | ILA15.20 Million ≈ $40.75K |
ILA3.28 Million ≈ $8.78K |
0.216x | -54.61% |
| 2010-12-31 | ILA8.18 Million ≈ $21.92K |
ILA3.88 Million ≈ $10.41K |
0.475x | +935.47% |
| 2009-12-31 | ILA1.55 Million ≈ $4.15K |
ILA71.00K ≈ $190.35 |
0.046x | -- |
About Bio-View Ltd
Bio-View Ltd develops, manufactures, and markets automated cell imaging and analysis solutions for use in cytology, cytogenetic, and pathology clinical and research laboratories in Israel and internationally. The company's products include Accord, a workbench microscope station for semi-automated fluorescent imaging and analysis; Accord Plus, an automatic fluorescent imaging system that automatic… Read more